The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-κ B to mediate survival and anchorage-independent growth of malignant mesothelioma cells

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1485-1493

  Catalano, Alfonso ^a   Lazzarini, Raffaella ^a,b   Nuzzo, Silvia Di ^a   Orciari, Silvia ^a   Procopio, Antonio ^a,b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE RECEPTOR; PLEXIN A1 RECEPTOR; SEMAPHORIN; SEMAPHORIN 6D; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CELL ADHESION; CELL DIVISION; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; GENES, REPORTER; HUMANS; IMMUNOBLOTTING; MESOTHELIOMA; NERVE TISSUE PROTEINS; NF-KAPPA B; PHENOTYPE; PLASMIDS; PLEURAL NEOPLASMS; RECEPTORS, CELL SURFACE; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 60549094267     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3659     Document Type: Article

References (33)

1. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006;42: 2706-14.
2. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75.
3. Robinson BW, Lake RA. Advances in malignant mesothelioma. NEngl J Med 2005;353:1591-603.
4. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functionalcompetitionofcollapsin-1 andvascularendothelial growth factor-165. J Cell Biol 1999;146:233-42.
5. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
6. Catalano A, Caprari P, Rodilossi S, et al. Crosstalk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J 2004; 18:358-60.
7. Matsushita A, Gotze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res 2007;67:10309-16.
8. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14:2532-9.
9. Parikh AA, Fan F, Liu WB. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004;164:2139-51.
10. Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther 2006;5:1099-107.
11. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell 1997;90:753-62.
12. Oinuma I, Ishikawa Y, Katoh H, Negishi M. The semaphorin 4D receptor plexin-B1 is a GTPase activating protein for R-Ras. Science 2004;305:862-5.
13. Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999;99:71-80.
14. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angio-genesis. Nat Rev Cancer 2008;8:632-45.
15. Toyofuku T, Zhang H, Kumanogoh A, et al. Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev 2004;18:435-47.
16. Bachelder RE, Lipscomb EA, Lin X, et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 2003;63:5230-3.
17. Rieger J, Wick W, Weller M. Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. Glia 2003;42:379-89.
18. Syed V Zhang X, Lau KM, Cheng R, Mukherjee K, Ho SM. Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 2005;24:8128-43.
19. Catalano A, Caprari P, Moretti S, Faronato M, Tamagnone L, Procopio A. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 2006;107:3321-9.
20. Moretti S, Procopio A, Lazzarini R, et al. Semaphor-in3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts. Blood 2008;111:2290-9.
21. Catalano A, Rodilossi S, Rippo MR, Caprari P, Procopio A. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 2004;279:46706-14.
22. Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A. Enhanced antitumor therapy by inhibition ofp21waf1 in human malignant mesothelioma. Clin Cancer Res 2008;14:5099-107.
23. Rolny C, Capparuccia L, Casazza A, et al. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 2008;205:1155-71.
24. Sierra JR, Corso S, Caione L, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 2008;205: 1673-85.
25. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathologyand genetics oftumours ofthe lung, pleura, thymus and heart. World Health Organization Classification of Tumours. Lyon: IARC Press; 2004.
26. Takegahara N, Takamatsu H, Toyofuku T, et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol 2006;8:615-22.
27. Stapelberg M, Gellert N, Swettenham E, et al. α-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. J Biol Chem 2005;280:25369-76.
28. Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002;62: 5242-7.
29. Bassères DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-30.
30. Cacciotti P, Barbone D, Porta C, et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005;65: 5256-62.
31. Toyofuku T, Zhang H, Kumanogoh A, et al. Guidance of myocardial patterning in cardiac development by Sema6D reverse signaling. Nat Cell Biol 2004;6:1204-11.
32. Emdad L, Sarkar D, Su ZZ, et al. Activation of the nuclear factor κB pathwaybyastrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res 2006;66:1509-16.
33. Catalano A, Romano M, Martinotti S, Procopio A. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene 2002;21:2896-900.